Sign in Subscribe
Cancer treatment

Modified hTERT Promoter-Directed Oncolytic Adenovirus for Breast Cancer Therapy

Strategic Insights

— 1 min read

A new approach to breast cancer therapy has been developed using a modified human telomerase reverse transcriptase (hTERT) promoter-directed oncolytic adenovirus that targets the TGFbeta pathway. Researchers from Northwestern University have created a virus, mhTERTAd.sTbetaRFc, that replicates in breast cancer cells while inhibiting TGFbeta signaling. The study demonstrates the potential of this approach as an antitumor agent.

Key Takeaways:

  • The modified hTERT promoter was found to be approximately 20 times more active in breast cancer cells compared to normal human cells.
  • Infection of MDA-MB-231 and MCF-7 breast cancer cells with mhTERTAd.sTbetaRFc produced high levels of sTGFbetaRIIFc (greater than 1 microg ml(-1)) in the medium.
  • Breast cancer cells produced a nearly 6000-fold increase in viral titers during the 48 h infection period, while mhTERTAd.sTbetaRFc replication was attenuated in normal cells.
  • Adenoviral-mediated production of sTGFbetaRIIFc was shown to abolish the effects of TGFbeta-1 on downstream SMAD-3 phosphorylation.
  • The administration of mhTERTAd.sTbetaRFc intravenously into MDA-MB-231 human xenograft-bearing mice resulted in a significant inhibition of tumor growth and production of sTGFbetaRIIFc in the blood.
  • These results warrant future investigation of mhTERTAd.sTbetaRFc as an antitumor agent in vivo.

Statistics:

  • The modified hTERT promoter was found to be approximately 20 times more active in breast cancer cells.
  • Breast cancer cells produced a nearly 6000-fold increase in viral titers during the 48 h infection period.
  • High levels of sTGFbetaRIIFc (greater than 1 microg ml(-1)) were produced in the medium after infection with mhTERTAd.sTbetaRFc.

Sources:

  • Cancer Gene Therapy, 2010;17(4):235-43, "A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy."
  • Northwestern University Department of Medicine, Evanston, IL.

Read more